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Introduction: The aim of this study was to evaluate the incidence and determinants of AKI in a large cohort of
cardiac arrest patients.
Methods: We reviewed all patients admitted, for at least 48 hours, to our Dept. of Intensive Care after CA between
January 2008 and October 2012. AKI was defined as oligo-anuria (daily urine output <0.5 ml/kg/h) and/or an
increase in serum creatinine (≥0.3 mg/dl from admission value within 48 hours or a 1.5 time from baseline level).
Demographics, comorbidities, CA details, and ICU interventions were recorded. Neurological outcome was assessed
at 3 months using the Cerebral Performance Category scale (CPC 1–2 = favorable outcome; 3–5 = poor outcome).
Results: A total of 199 patients were included, 85 (43%) of whom developed AKI during the ICU stay. Independent
predictors of AKI development were older age, chronic renal disease, higher dose of epinephrine, in-hospital CA,
presence of shock during the ICU stay, a low creatinine clearance (CrCl) on admission and a high cumulative fluid
balance at 48 hours. Patients with AKI had higher hospital mortality (55/85 vs. 57/114, p = 0.04), but AKI was not an
independent predictor of poor 3-month neurological outcome.
Conclusions: AKI occurred in more than 40% of patients after CA. These patients had more severe hemodynamic
impairment and needed more aggressive ICU therapy; however the development of AKI did not influence
neurological recovery.Introduction
Most studies on patients after resuscitated cardiac arrest
(CA) have focused on survival or the extent of brain
dysfunction [1]; the prevalence of extra-cerebral organ
injury and its impact on outcome has been less well-
characterized [2]. After return of spontaneous circula-
tion (ROSC), myocardial dysfunction and the systemic
ischemia/reperfusion response can lead to the so-called
post cardiac arrest syndrome, which is characterized by
the activation of immunologic and coagulation pathways
and the release of inflammatory mediators, all leading to
tissue hypoperfusion and multiple organ dysfunction [3].
Recently, Roberts et al. [4] reported that 96% of a co-
hort of 203 patients resuscitated after CA had some de-
gree of organ dysfunction, in particular cardiovascular
and respiratory impairment; two-thirds of these patients
had at least two extra-cerebral organ dysfunctions. Only
alterations in the cardiovascular and respiratory system,
assessed by the sequential organ failure assessment* Correspondence: ftaccone@ulb.ac.be
Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles
(ULB), Route de Lennik, 808, Brussels 1070, Belgium
© 2015 Tujjar et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.(SOFA) subscores [5], were independently associated
with in-hospital mortality.
Several studies have also highlighted the high preva-
lence of acute kidney injury (AKI) in CA patients and
how this may influence patient outcome in this setting.
Domanovits et al. [6] showed that 12% of CA patients
developed AKI within 24 h after admission; in particular,
congestive heart failure, history of hypertension and the
total dose of epinephrine administered during cardiopul-
monary resuscitation (CPR) were independent predictors
of AKI. However, AKI was defined as a 25% decrease
in creatinine clearance (CrCl) using the Cockroft-Gault
formula, instead of the currently recommended combin-
ation of changes in serum creatinine and urine output [7].
In addition, this study was conducted before the imple-
mentation of therapeutic hypothermia (TH), which may
be associated with enhanced protection of visceral organs
[8]. Other studies report that AKI occurs in 30 to 50% of
CA patients and is associated with high levels of bio-
markers of brain injury, the presence of cardiogenic shock
and inadequate fluid therapy [9-11]. Nevertheless, the
association of AKI with survival remains unclear [9,12].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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potentially nephrotoxic agents (for example, contrast
media, aminoglycosides), the development of sepsis during
the ICU stay, which can significantly increase the risk of
AKI, and the amount and type of fluid administered after
hospital admission, as potential risk factors. Augmented
renal clearance (ARC) can also occur in critically ill pa-
tients and is associated with poor outcome, but the occur-
rence and the impact of ARC in CA patients have not
been well-studied [13,14].
Finally, AKI may have an impact on neurological recovery.
In an experimental model of renal injury, AKI was found to
contribute to the inflammatory injury in the hippocampus,
altered blood–brain barrier permeability and potentiated
oxidative stress in the cerebral tissue [15,16]. Patients with
AKI also have a higher incidence of stroke and cognitive dis-
orders than patients without AKI [17,18]. Nevertheless, the
association of AKI and long-term neurological recovery has
not been well-studied in CA patients. The aim of this study
was, therefore, to evaluate the incidence and the determi-
nants of AKI in a large cohort of CA patients, as well as the
occurrence of ARC and the association of changes in renal
function with neurological outcome.
Methods
Study population
This retrospective study was performed in the Department
of Intensive Care at Erasme Hospital, Brussels. The local
Ethical Committee (Comité d’Ethique Hospitalo-Facultaire
Erasme-ULB) approved the study, but waived the need for
informed consent because the study was purely observa-
tional. The study was performed in accordance with the
ethical standards of the 1964 Declaration of Helsinki and
its later amendments. All comatose patients (Glasgow coma
scale (GCS) score <9) admitted after in-hospital CA
(IHCA) or out-of-hospital CA (OHCA) (January 2008 to
October 2012) were included in an institutional database,
provided that they survived for at least 48 h after CA, so
that at least three serum creatinine (sCr) measurements
were obtained. Exclusion criteria were missing data on
creatinine or urine output, AKI (for IHCA) before the oc-
currence of CA and chronic renal failure requiring
hemodialysis.
Post-resuscitation care
All these patients were treated with TH, targeting a body
temperature between 32 and 34°C for 24 h, according to a
standardized institutional protocol, including the use of a
cold fluid bolus (20 to 30 mL/kg saline or a balanced crys-
talloid solution over 30 minutes) and of a water-circulating
blanket device (Medi-Therm II, Gaymar, Orchard Park, NY,
USA). Midazolam (continuous infusion 0.03 to 0.1 mg/kg/
h) and morphine (0.1 to 0.3 mg/kg/h) were administered
during the hypothermic phase, while neuromuscularblocking agents (NMBAs, cisatracurium as a bolus of
0.15 mg/kg) were given in the induction phase and, if
needed, as a continuous infusion thereafter (1 to 3
mcg/kg/min). Re-warming was performed passively at
a maximum rate of 0.5°C/h; sedation, analgesia and
NMBAs were discontinued when the body temperature
exceeded 37°C.
Patients were kept in a 30° semi-recumbent position;
ventilation was set to maintain arterial partial pressure
of carbon dioxide (PaCO2) at 35–45 mmHg and periph-
eral capillary oxygen saturation (SpO2) >94%. Invasive
hemodynamic monitoring (PiCCO, Pulsion, Munich,
Germany) was placed whenever needed and transeso-
phageal echocardiography was performed within the first
8 to 12 h after ICU admission in all patients. Mean arterial
pressure (MAP) was maintained at >65 to 70 mmHg using
fluids, dobutamine and/or norepinephrine, whenever
needed. Higher levels of MAP were targeted in patients
with a history of hypertension and in patients with low
(<60%) cerebral oximetry values (Foresight, CasMed,
Branford, CT, USA). Intra-aortic balloon counterpulsation
(IABP) or extracorporeal membrane oxygenation (ECMO)
was initiated in cases of severe cardiogenic shock. A local
insulin protocol was applied to keep blood glucose levels
between 110 and 150 mg/dL in all patients.
After re-warming the patient and stopping sedative
agents, repeated neurologic examination and standard or
continuous electroencephalogram (EEG) were performed.
Withdrawal of life-support was an interdisciplinary deci-
sion based on bilateral absence of the N20 response to
somatosensory evoked potentials (SSEPs), persisting deep
coma, or presence of status myoclonus or refractory status
epilepticus.
Data collection
We collected data on demographics, pre-existing chronic
diseases and CPR (that is, first rhythm, bystander CPR,
time to ROSC, total epinephrine dose) in all patients.
Serum creatinine levels on ICU admission were recorded,
as was the CrCl on the first day of therapy, calculated
from the 24-h urine collection, according to the following
formula:
CrCl;mL=min ¼ Urine output;mLð Þ  Urine creatinine;mg=dLð Þð Þ
 sCr;mg=dLð Þ  Urine collection; minð Þ½ Þ:
sCr and urine output were collected daily during the
entire ICU stay. Daily fluid balance and the administration
of hydroxyethyl starch (HES) solutions were also noted.
We also recorded use of any potentially nephrotoxic
agents, including intravenous contrast media, angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin II re-
ceptor blockers (ARBs), non-steroidal anti-inflammatory
drugs (NSAIDs), aminoglycosides, amphotericin B, colistin
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inhibitors, such as cyclosporine and tacrolimus). Treat-
ments with vasoactive drugs, mechanical ventilation, and
continuous renal replacement therapy (CRRT) were re-
corded, as were length of ICU stay and ICU and hospital
outcome. Neurological evaluation at 3 months after CA
was assessed using the cerebral performance category
score (CPC; 1 = no neurological disability, 2 =mild neu-
rological disability, 3 = severe neurological impairment,
4 = vegetative state, 5 = death). The CPC evaluation was
assessed during follow-up visits or by telephone inter-
view with the general practitioner.
Definitions
AKI was defined as a daily urine output <0.5 mL/kg/h
and/or an increase in sCr level by at least 0.3 mg/dL
or >1.5 time increase from baseline values [19]. In par-
ticular, the criterion of ≥0.3 mg/dL rise from baseline
values occurred within 48 h and was not used with any
previous chronic renal disease or in the absence of base-
line sCr. We considered only daily urine output, because
this measure may be influenced less by the effects of
specific therapies, such as volume loading and diuretic
administration, compared to shorter periods. Baseline sCr
was collected from the patient’s medical records within
one year prior to the CA (if multiple values were available,
the last one was collected). When a baseline sCr was not
available (n = 10, all with OHCA), it was estimated using
the Modification of diet in renal disease (MDRD) study
equation, which provides sCr values based on the glom-
erular filtration rate calculated by age, race and sex [20].
Chronic kidney disease (CKD) was identified as CKD
stage 3 according to the recent definitions [21]. For pa-
tients with CKD and those with estimated baseline sCr,
the criterion of sCr increase >1.5 times the baseline value
was used. The more severe AKI stage during the ICU stay
[19] as well as the time to AKI since ICU admission was
also noted. ARC was defined as a CrCl of 130 mL/min or
greater [22]. Shock was defined as the need for vasopres-
sor agents for more than 6 h. The diagnosis of infection
was based on the combination of clinical or radiological
signs of an infectious process with a positive culture from
a normally sterile site (for example, blood culture, bron-
choalveolar lavage (BAL) or endotracheal aspirate) and
the need for antibiotic administration. The site of infection
was defined using the CDC/NHSN criteria [23]. A fa-
vorable neurological outcome was defined as a CPC
of 1 or 2 at 3 months; poor neurological outcome as a
CPC of 3 to 5.
Statistical analysis
Statistical analyses were performed using the SPSS 18.0
for Windows NT software package (SPSS Inc. 2004,
Chicago, IL, USA). Descriptive statistics were computedfor all study variables. The Kolmogorov-Smirnov test was
used, and histograms and normal-quantile plots were
examined to verify the normality of distribution of con-
tinuous variables. Discrete variables were expressed as
counts (percentage) and continuous variables as means ±
SD or median (25th to 75th percentiles). Demographics
and clinical differences between groups (AKI versus no
AKI; favorable versus poor neurological outcome) were
assessed using the chi-square test, Fisher’s exact test, Stu-
dent’s t-test, or Mann–Whitney U-test, as appropriate.
The significance of differences in sCr between groups was
analyzed using two-way (time and group) analysis of
variance for repeated measures (ANOVA), followed by
Bonferroni post-hoc analysis. Multivariable logistic regres-
sion analysis with AKI development as the dependent
variable was performed in all patients. Colinearity between
variables was excluded prior to modelling; only variables
associated with a higher risk of AKI (P <0.2) on a uni-
variate basis were introduced in the multivariate model.
Odds ratios (OR) with 95% confidence intervals (CI)
were computed. The same analysis was then performed
to identify independent predictors of favorable neurolo-
gical outcome. A P-value <0.05 was considered as statis-
tically significant.
Results
Of the 253 CA patients eligible over the study period, 54
were excluded (n = 51 for missing data on sCr/urine
output; n = 3 because they were receiving chronic
hemodialysis - hospital mortality 29/51 (57%) and favor-
able neurological outcome 19/51 (37%)) and 199 were
included in the final cohort (Figure 1). The main cha-
racteristics of the study population are shown in Table 1.
Sixty-nine patients had CA of non-cardiac origin (respi-
ratory failure with severe hypoxemia, n =45; septic shock,
n = 16; drug overdose, n = 5; trauma, n = 1; drowning, n = 1;
hanging, n = 1). Overall ICU survival was 46% and 81
patients (41%) had a favorable neurological outcome at
3 months.
Eighty-five patients (43%) developed AKI, after a me-
dian of 2 (2, 3) days; CKD was found in 21 patients (25%
of the AKI patients) and CRRT was used in 24 patients
(29% of the AKI patients) (Figure 2). A total of 34 pa-
tients (40%) developed AKI stage 1, 22 (26%) AKI stage
2 and 29 (34%) AKI stage 3; the distribution of AKI
stages was similar according to the initial criterion of
AKI diagnosis (Figure 3; P = 0.19). Patients who devel-
oped AKI were significantly older than those who did
not, were more likely to have chronic heart failure, pre-
existing neurological or renal disease, and to be already
receiving steroid or diuretic therapy. Patients who devel-
oped AKI also more frequently had a witnessed and
IHCA than other patients, related to the larger number of
witnessed CA among patients with IHCA than OHCA
Figure 1 Flow-chart of the study. sCr, serum creatinine; CA, cardiac arrest; UO, urine output.
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veloped AKI had a longer time to ROSC and received
more epinephrine during CPR than other patients. These
patients were also more likely to have shock, to be treated
with vasopressors and dobutamine, and to have a longer
duration of mechanical ventilation during the ICU stay
than those who did not develop AKI. Finally, patients who
developed AKI received more nephrotoxic agents, in par-
ticular aminoglycosides, had a greater fluid balance over
the first 2 days after ICU admission and were more likely
to receive diuretics during the ICU stay. Patients who
developed AKI had greater hospital mortality (65% versus
50%, p = 0.04) than those who did not and there was a
trend towards fewer patients with a favorable neurological
outcome at 3 months (34% versus 46%, P = 0.08). Thirty-
eight patients (19%) had ARC on the first day after ICU
admission, and six of them eventually developed AKI,
after a median of 3 (range 2 to 5] days; only one patient
needed CRRT.
In multivariable regression analysis, older age, larger
epinephrine dose during CPR, the occurrence of shock
during the ICU stay, higher 48-h fluid balance and
chronic renal disease were independent predictors of
AKI after CA. Augmented CrCl on the first day of the
ICU stay and OHCA were protective factors against AKI
development (Table 2).
Patients with a favorable 3-month neurological out-
come were younger, more frequently male, and less
likely to have a history of heart failure than those with
poor neurological outcome; they had also more frequently
had a witnessed CA, bystander CPR, initial shockable
rhythm, lower epinephrine dose, CA of non-cardiac origin,shorter time to ROSC, less commonly had shock during
the ICU stay, had a lower blood lactate level on admission
and required lower doses of vasopressors and dobutamine.
There were no significant differences in sCr levels during
the first 3 days of ICU admission between patients with fa-
vorable and poor neurological outcomes (Figure 4). Hos-
pital mortality was higher, although not statistically
significant, for those patients diagnosed with AKI using sCr
or combined sCr/UO criteria than in those diagnosed by
UO alone (20/29 versus 22/13 versus 13/25, respectively;
P = 0.28). Similar results were found for a 3-month fa-
vorable neurological outcome (8/28 versus 9/31 versus
12/25, respectively, P = 0.24). The development of ARC,
AKI or need for CRRT had no significant impact on
neurological outcome (Figure 5). In a multivariable ana-
lysis, younger age, shockable rhythm, bystander CPR, a
shorter time to ROSC, lower dose of epinephrine during
CPR, the absence of shock during the ICU stay and lower
blood lactate level on ICU admission were independent
factors associated with a favorable 3-month neuro-
logical outcome (Table 3).
Discussion
AKI developed in 43% of patients resuscitated after CA
and more than 75% of these episodes occurred within
3 days after CA. Almost one third of these patients with
AKI eventually needed CRRT. Patients who developed
AKI not only took longer for ROSC, but also more fre-
quently had pre-existing cardiac and renal disease, had
more severe hemodynamic alterations, a more positive
fluid balance and received more nephrotoxic agents. How-
ever, although patients with AKI had increased hospital
Table 1 Characteristics of the study population according to the development of acute kidney injury (AKI)
All patients (n = 199) No AKI (n = 114) AKI (n = 85) P-value
Age, years 62 ± 16 60 ± 14 65 ± 10 0.001
Weight, kg 77 ± 22 76 ± 22 78 ± 20 0.45
Male, n (%) 134 (67) 80 (70) 54 (64) 0.29
Total ICU stay, days 4 (3 to 8) 4 (3 to 7) 5 (3 to 9) 0.03
Witnessed CA, n (%) 148 (74) 77 (68) 71 (84) 0.009
Bystander CPR, n (%) 112 (56) 63 (55) 49 (58) 0.67
Time to ROSC, minutes 15 (9 to 26) 15 (9 to 22) 16 (10 to 30) 0.04
Epinephrine, mg 4 (2 to 7) 4 (2 to 6) 4 (3 to 8) 0.03
Out-of-hospital CA 121 (61) 80 (70) 41 (48) 0.002
Non cardiac-origin CA 69 (35) 44 (39) 25 (29) 0.22
VF/VT, n (%) 118 (59) 48 (42) 33 (39) 0.66
Past history
Chronic heart failure, n (%) 57 (29) 25 (22) 32 (38) 0.02
Hypertension, n (%) 77 (39) 42 (37) 35 (41) 0.56
Coronary artery disease, n (%) 86 (43) 45 (39) 41 (48) 0.25
Diabetes, n (%) 42 (21) 19 (17) 23 (27) 0.08
COPD/asthma, n (%) 37 (19) 24 (21) 13 (15) 0.36
Neurological disease, n (%) 30 (15) 22 (19) 8 (9) 0.07
Chronic renal disease, n (%) 30 (15) 9 (8) 21 (25) 0.001
Liver cirrhosis, n (%) 11 (6) 4 (4) 7 (8) 0.13
HIV, n (%) 1 (1) 1 (1) 0 1.00
Corticosteroid therapy, n (%) 29 (15) 12 (11) 17 (20) 0.07
Immunosuppressive agents, n (%) 2 (1) 0 2 (2.3) 0.09
Therapy before ICU admission
IECA/ ARBs, n (%) 81 (41) 43 (38) 38 (45) 0.38
Diuretics, n (%) 40 (20) 15 (13) 25 (29) 0.008
Aminoglycosides, n (%) 1 (1) 0 1 (1) 0.21
Amphotericin B, n (%) 0 0 0 -
Cyclosporine/FK506, n (%) 0 0 0 -
NSAIDs, n (%) 68 (34) 37 (32) 31 (36) 0.58
Chemotherapy, n (%) 0 0 0 -
Events and interventions during ICU stay
Lactate on admission, mEq/L 3.1 (1.9 to 5.1) 3.1 (1.8 to 5.2) 3.3 (2.0 to 6.6) 0.288
Infection, n (%) 123 (62) 66 (58) 57 (67) 0.21
IABP, n (%) 15 (8) 6 (5) 9 (11) 0.12
ECMO, n (%) 22 (11) 9 (8) 13 (16) 0.08
Shock, n (%) 103 (52) 43 (38) 60 (71) 0.002
Therapeutic hypothermia, n (%) 198 (99) 114 (100) 84 (99) 0.96
MV, n (%) 199 (100) 114 (100) 85 (100) -
Duration of MV, days 3 (2 to 5) 3 (2 to 4) 4 (3 to 7) 0.001
Fluid balance on day 1, mL/day 1,924 ± 1348 1,480 ± 1348 2,520 ± 1414 0.001
Fluid balance on day 2, mL/day 2,704 ± 1636 2,282 ± 1639 3,264 ± 2889 0.003
CrCl on day 1, mL/min 40 (13 to 90) 67 (27 to 121) 23 (9 to 44) <0.001
Augmented renal clearance on day 1, n (%) 38 (19) 32 (28) 6 (7) 0.001
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Table 1 Characteristics of the study population according to the development of acute kidney injury (AKI) (Continued)
CRRT, n (%) 24 (12) 0 24 (29) 0.001
Therapy during ICU stay
Vasopressor therapy, n (%) 134 (68) 65 (57) 69 (81) 0.001
Duration of vasopressor therapy, days 3 (2 to 5) 3 (2 to 4) 4 (3 to 6) 0.001
Cumulative vasopressor dose, mcg 21.0 (7.7-73.2) 9.9 (4.1-29.9) 39.1 (14.6-109.7) 0.001
Dobutamine therapy, n (%) 112 (56) 40 (35) 72 (85) 0.001
Duration of dobutamine, days 3.5 (3 to 6) 3 (2 to 4) 4 (3 to 6) 0.001
Cumulative dobutamine dose, mcg 1456 (514 to 2733) 982 (445 to 1670) 2084 (575 to 3964) 0.001
ACEIs/ARBs, n (%) 54 (27) 36 (32) 18 (21) 0.11
Diuretics, n (%) 94 (47) 45 (40) 49 (57) 0.01
Aminoglycosides, n (%) 38 (19) 15 (13) 23 (27) 0.01
Amphotericin B, n (%) 1 (1) 1 (1) 0 -
Cyclosporine/FK506, n (%) 2 (1) 0 2 (2) 0.92
NSAIDs, n (%) 90 (45) 49 (43) 41 (48) 0.48
Chemotherapy, n (%) 2 (1) 0 2 (2) 0.86
Contrast medium, n (%) 94 (47) 51 (45) 43 (51) 0.41
Contrast medium injections, n (%) 0 (0 to 1) 0 (0 to 1) 1 (0 to 2) 0.19
HES, n (%) 14 (7) 8 (7) 6 (7) 0.99
Number of nephrotoxic agents, n (%) 2 (1 to 3) 1 (0 to 3) 2 (1 to 3) 0.04
At least one nephrotoxic agent, n (%) 158 (79) 83 (72) 75 (88) 0.008
Outcomes
ICU mortality, n (%) 107 (54) 55 (48) 52 (61) 0.08
Hospital mortality, n (%) 112 (56) 57 (50) 55 (65) 0.04
Favorable neurological outcome at 3 months, n (%) 81 (41) 52 (46) 29 (34) 0.11
Results are expressed as mean ± SD, median (IQR) or number (%). CA, cardiac arrest; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation;
VF/VT, ventricular fibrillation/ventricular tachycardia; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump counterpulsation; ECMO,
extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor
blockers; NSAIDs, non-steroidal anti-inflammatory drugs; HES, hydroxyethyl starch; CrCl, creatinine clearance; MV, mechanical ventilation.
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significantly different rates of survival with a favourable
neurological outcome.
Other studies have reported lower rates of AKI after
CA, ranging from 12 to 43% [10,24,25]. These differ-
ences may be due to using different definitions of AKI,
which in some studies included a fixed cutoff for sCr
(>1.4 mg/dL) [24,25] rather than relative changes in
creatinine from baseline values and UO. Moreover,
some of the previous studies included only OHCA
patients, whereas IHCA may be associated with dif-
ferent risk factors for AKI and for poor outcome
[6,11,12,24]. Also, TH was used inconsistently in the
other studies [9,11,12] and the time course of AKI was
not reported.
As expected, AKI was more common in the presence
of pre-existing renal dysfunction. This has been reported
in other studies, in which conditions such as congestive
heart failure or diabetes, which are associated with re-
duced renal function, were independent predictors of
AKI after CA [6,24]. The association between IHCA andthe occurrence of AKI may also reflect pre-existing dis-
ease leading to hospital admission and that could have
predisposed the kidney to further injury after CA [26].
Older age was associated with an increased risk of AKI,
as also suggested in a study by Yanta et al. [12], likely
because of the physiological decrease in the renal re-
serve. The presence of shock was an independent pre-
dictor of AKI, as also reported in another study, which
showed that AKI occurred in under 10% of hemody-
namically stable CA patients [10]. Acute tubular necrosis
is uncommon in postmortem studies of patients dying of
shock [27]. A study by Chang et al. suggests that glomeru-
lar barrier dysfunction and vascular hyperpermeability
may also play an important role in the pathogenesis of
post-CA renal dysfunction [28]. Patients with AKI
also received greater cumulative epinephrine doses than
others; vasoconstrictors can induce alterations in intra-
renal hemodynamics [29] and epinephrine may worsen
the function of all organs, as suggested by alterations in
cerebral microcirculation and lung exchange or in-
creased post-resuscitation myocardial dysfunction observed
Figure 2 Diagnosis of acute kidney injury (AKI) in patients suffering from out-of-hospital cardiac arrest (OHCA) or in-hospital (IHCA)
cardiac arrest. Among patients with previous chronic renal disease (CKD), diagnosis of AKI was initially based on the increase of serum creatinine
(sCr) of at least 1.5 times the baseline values or the reduction in daily urine output (UO) or both. Among patients without previous chronic renal
disease (No CKD), diagnosis of AKI was initially based on the increase of serum creatinine (sCr) ≥0.3 mg/dL from the baseline value or the
reduction of daily urine or both. For each group, the number of patients eventually treated with continuous renal replacement therapy (CRRT)
was reported.
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of post-resuscitation shock is multifactorial and en-
compasses systemic inflammatory response, myocardial
stunning or adrenal insufficiency, our findings highlight
that post-resuscitation disease plays a crucial role in theFigure 3 Proportion of patients developing acute kidney injury (AKI)
serum creatinine (sCr) criterion, the urine output (UO) criterion or bodevelopment of AKI and that identification of patients
at risk could promote the development of nephro-
protective strategies (for example, antioxidants, ARBs,
phosphodiesterase inhibitors) in order to reduce AKI
occurrence in such patients.stage 1, 2 or 3 according to the diagnosis of AKI based on the
th.
Table 2 Multivariable analysis to identify the independent predictors of development of acute kidney injury after
cardiac arrest
Variable P-value Odds ratio 95% CI for odds ratio
Lower Upper
Age, years 0.027 1.030 1.003 1.057
Epinephrine, mg 0.004 1.198 1.059 1.356
Out-of-hospital cardiac arrest 0.006 0.289 0.118 0.706
Shock during ICU stay 0.026 2.855 1.133 7.195
Chronic renal disease 0.024 4.466 1.222 16.318
Fluid balance at 48 h, L 0.047 1.120 1.020 1.200
Creatinine clearance on day 1, mL/min 0.015 0.991 0.984 0.998
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after arrest and AKI is also an important finding. Indeed,
on one hand the maintenance of adequate circulating
blood volume is essential to preserve renal perfusion:
Adler et al. showed that fluid therapy guided by volu-
metric and arterial waveform-derived variables could
reduce the incidence of AKI in patients with cardiogenic
shock after CA [11]. By contrast, there is growing evi-
dence that liberal fluid therapy might have detrimental
effects in critically ill patients and that the type of fluid
could have significant effects on renal injury [31]. In our
study, the proportion of patients receiving HES was
similar in patients who developed AKI and those who
did not, but even chloride-rich crystalloid solutions may
increase the risk of AKI [32]. Importantly, fluid resus-
citation may also potentially dilute sCr and delay the
diagnosis of AKI. This was elegantly shown by Pickering
et al. [33] in a study evaluating 49 CA patients; AKI was
observed in 6 patients demonstrating only minor
changes in sCr but significantly increased biomarkers of
renal injury. The changes in sCr among CA survivors
may also be related to a temporary reduction of creatinine
production (that is, due to the decreased non-enzymaticFigure 4 Time course of median serum creatinine over the first
3 days following ICU admission in patients with favorable (FNO)
and poor (PNO) neurological outcomes.conversion of creatine to creatinine induced by the use of
hypothermia or due to immobilization) [34,35]. The clin-
ical consequence is that sCr alone may underestimate the
occurrence and severity of AKI; thus, the UO evaluation is
of great importance in this setting as it was shown to ad-
equately identify AKI in most of these patients without
sCr changes after CA.
As all patients were treated with TH after CA, we
could not evaluate any protective role of cooling on
renal function. Some studies showed that TH had bene-
ficial effects on renal function after experimental CA or
renal transplantation by reducing the extent of ischemia-
reperfusion renal injury [36,37]. In a meta-analysis that
also included post-cardiac surgery patients, Susantita-
phong et al. suggested that TH did not protect renal
function, although lower targets of cooling temperature
were associated with lower risk of AKI [38]. In CA pa-
tients, two studies found that hypothermia was associ-
ated with an increased risk of AKI and a longer periodFigure 5 Proportion of patients with favorable neurological
outcome according to the presence of augmented renal
clearance (ARC) without acute kidney injury (AKI), normal renal
function (no AKI), AKI or AKI requiring continuous renal
replacement therapy (CRRT).
Table 3 Univariable and multivariable analyses to assess variables independently associated with favorable
neurological outcome at 3 months
Variable Favorable neurological
outcome (n = 81)
Poor neurological
outcome (n = 118)
Univariate analysis Multivariate analysis
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Acute kidney injury, n (%) 29 (36) 56 (47) 0.664 (0.368, 1.197] 0.17
Age, years 58 (49 to 71) 66 (53 to 77) 0.981 (0.963, 0.999) 0.04 0.963 (0.937, 0.990) 0.007
Weight, kgs 77 (70 to 90) 75 (65 to 85) 1.012 (0.993, 1.031) 0.24
Male, n (%) 63 (78) 71 (60) 2.622 (1.341, 5.126) 0.005
Witnessed CA 70 (87) 78 (66) 2.695 (1.283, 5.664) 0.009
Bystander CPR, n (%) 60 (74) 52 (44) 2.823 (1.526, 5.224) 0.001 3.682 (1.522, 8.908) 0.004
Time to ROSC, min 13 (7 to 21) 18 (10 to 27) 0.980 (0.958, 1.002) 0.07 1.085 (1.009, 1.167) 0.03
Epinephrine, mg 3 (1 to 5) 5 (3 to 7) 0.846 (0.766, 0.935) 0.001 0.594 (0.439, 0.804) 0.001
Out- of-hospital CA 45 (56) 76 (64) 0.836 (0.465, 1.503) 0.55
Non-cardiac origin CA 18 (22) 51 (43) 0.297 (0.150, 0.586) <0.001
VF/VT, n (%) 52 (64) 29 (25) 3.858 (2.925, 4.710) <0.001 3.797 (2.922, 4.539) <0.001
Infection during ICU stay, n (%) 49 (60) 74 (63) 1.165 (0.640, 2.121) 0.63
IABP during ICU stay, n (%) 6 (7) 9 (8) 1.137 (0.388, 3.334) 0.82
ECMO during ICU stay, n (%) 10 (12) 12 (10) 1.193 (0.483, 2.943) 0.70
Shock during ICU stay, n (%) 36 (44) 67 (57) 0.531 (0.296, 0.950) 0.03 0.433 (0.187, 0.998) 0.049
Corticosteroid therapy, n (%) 10 (12) 19 (16) 0.720 (0.309, 1.677) 0.45
Chronic heart failure, n (%) 20 (24) 37 (31) 0.502 (0.255, 0.989) 0.05
Hypertension, n (%) 28 (35) 49 (42) 0.786 (0.433, 1.426) 0.43
Coronary artery disease, n (%) 37 (46) 49 (42) 1.093 (0.612, 1.952) 0.76
Diabetes, n (%) 16 (20) 26 (22) 0.705 (0.340, 1.462) 0.35
COPD/asthma, n (%) 17 (21) 20 (17) 1.190 (0.574, 2.470) 0.64
Neurological disease, n (%) 9 (11) 21 (18) 0.686 (0.296, 1.589) 0.38
Chronic renal disease, n (%) 11 (14) 19 (16) 0.813 (0.358, 1.846) 0.62
Liver cirrhosis, n (%) 2 (2) 9 (8) 0.358 (0.075, 1.704) 0.19
Vasopressor therapy, n (%) 50 (62) 84 (71) 0.628 (0.342, 1.151) 0.13
Duration of vasopressor
therapy, days
4 (2 to 5) 3 (2 to 5) 1.032 (0.918, 1.159) .060
Cumulative vasopressor dose, mcg 10.5 (3.8, 28.8) 31.0 (11.1, 101.8) 0.992 (0.986, 0.999) 0.02
Dobutamine therapy, n (%) 39 (48) 55 (47) 0.900 (0.650, 1.246) 0.53
Cumulative dobutamine dose, mcg 964 (274 to 1978) 1746 (722 to 3378) 1.002 (1.001, 1.009) 0.04
Duration of MV, days 3 (2 to 5) 3 (2 to 5) 1.052 (0.975, 1.136) 0.19
CRRT, n (%) 11 (14) 13 (58) 1.491 (0.631, 3.525) 0.36
Lactate on admission, mEq/L 2.4 (1.6, 3.8) 3.8 (2.1, 6.8) 0.844 (0.758, 0.940) 0.002 0.864 (0.746, 0.999) 0.049
Fluid balance at 48 h, mL 3714 (1867 to 5970) 4197 (2575 to 6729) 1.199 (0.875, 1.342)* 0.53
CrCl on day 1, mL/min 54 (23 to 92) 33 (11 to 78) 1.002 (0.998, 1.007) 0.32
Results are expressed as median (IQR) or number (%). *Per liter of fluid balance. CA, cardiac arrest; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous
circulation; VF/VT, ventricular fibrillation/ventricular tachycardia; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump counterpulsation; ECMO,
extracorporeal membrane oxygenation; MV, mechanical ventilation; CVVH, continuous veno-venous hemofiltration; CrCl, creatinine clearance.
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se be deleterious to renal function but may reflect more
severe and longer duration of ischemic injury. Further
studies are needed to better define the role of TH on
renal protection after CA.For the first time, we evaluated the prevalence and the
impact of ARC in patients surviving CA; 19% of these
patients had ARC on ICU admission, with more than
40% surviving with good neurological recovery at 3 months
after arrest. ARC is present in 50 to 65% of the general
Tujjar et al. Critical Care  (2015) 19:169 Page 10 of 12ICU population on admission, and usually persists over
subsequent days [13,40]. In our study, although ARC
on admission was independently associated with a
lower risk of developing AKI, it had no impact on
neurological outcome. However, ARC may have other
unwanted effects, such as increased elimination of anti-
biotics, which may expose patients to insufficient drug
concentrations in the presence of infection, increased
elimination of sedative agents that may complicate
temperature control in this setting, and other difficul-
ties in appropriate drug dosing, for example, in the case
of seizures [13,41].
Our data provide no evidence that development of
AKI contributes to poor neurological outcome in the
setting of CA. By contrast, Hasper et al. report that the
development of AKI is associated with a lower probabil-
ity of favorable neurological outcome (72.5% versus
47.1%, P = 0.013) [9]. All other studies on the impact of
AKI in CA patients evaluated only mortality. As such,
Yanta et al., in a large cohort of 311 patients with
OHCA, found that AKI had no impact on hospital sur-
vival [12]. Roberts et al. reported that extra-cerebral
organ dysfunction was common after CA but only car-
diovascular dysfunction and altered gas exchange were
associated with outcome [4]. It is very difficult to com-
pare these studies, because the measured outcomes were
diverse (that is, hospital survival, favorable neurological
outcome at hospital discharge and favorable neurological
outcome at 3 months), the number of patients treated
with TH was different, and so was the proportion of
patients with OHCA. Importantly, as a decision to with-
draw therapy is made in a number of patients with exten-
ded post-CA brain injury, regardless of the development
of AKI, it is not possible to assess the impact of AKI on
such decisions. Other factors, such as time to ROSC, total
amount of epinephrine, presentation rhythm, bystander
CPR and age, had a greater impact on neurological out-
come than the development of AKI.
The study has some limitations. First, as a retrospect-
ive study, we may have missed some confounders that
could influence the development of AKI. However, we
collected a large amount of clinical data from the med-
ical files, as well as data related to CA characteristics
and the administration of potential nephrotoxic agents
to minimize this bias. Of course, the generalizability
of these findings may be limited because of different
therapeutic strategies in the management of CA pa-
tients within other centers, which may influence both
AKI occurrence and overall outcome. Second, during
the four years of study enrolment, management of
CA treatment may have changed somewhat [42], al-
though this is unlikely to have influenced the occur-
rence of AKI over this relatively short period. Third,
we did not assess the occurrence of rhabdomyolysis;although its incidence after CA remains largely un-
known, elevation in creatine phosphokinase levels
may contribute to severe AKI in this setting [43].
Moreover, rhabdomyolysis could be associated with
marked creatinine release from skeletal muscle, which
may theoretically influence the course of sCr. Fourth,
we did not record other findings from urine analysis,
such as proteinuria or specific gravity, although these
have been associated with patient outcome after CA
[28]. Also, we did not use the standard UO criteria
for AKI stage 1 (that is <0.5 mL/kg/h for 6 h) and
this may have underestimated the occurrence of AKI
stage 2 and/or stage 3 in our population. Fifth, the
number of patients with poor neurological outcome
surviving at hospital discharge was quite limited and
was significantly influenced by the short-term sur-
vival. Thus, it is difficult to make a conclusion on the
influence of AKI on neurological recovery, given the
analysis is dominated by death. However, no more
than 10% of CA patients with post-anoxic severe dis-
ability or vegetative status are discharged alive from
the hospital and only a few of them have improvement of
their long-term neurological status [44]. Sixth, for in-
hospital CA, we used sCr at hospital admission as the
baseline value and this may have been influenced by the
underlying reason for admission. Also, we did not adjust
our results using different scores for comorbidity, such
as the Charlson, Davies or Khan indices, which have
been shown to predict outcome in patients with end-
stage renal disease [45]. Nevertheless, the predictive
value of such scores in patients with CA remains con-
troversial [46]. Finally, we did not assess long-term
renal function in CA survivors. However, Chua et al.
showed that creatinine levels on discharge were simi-
lar to baseline values in such patients, and that none
of those being treated with CRRT during their ICU
stay needed long-term hemodialysis thereafter [10].
Conclusions
In this cohort, AKI occurred in almost half the patients
who survived CA; however, it was not an independent
prognostic factor for poor outcome. Age, epinephrine
dose, cumulative fluid balance and presence of shock
were independent predictors of the development of AKI
in this population. ARC occurred in almost 20% of pa-
tients and was associated with reduced incidence of AKI.
Renal failure had no clear correlation with poor neuro-
logical outcome.
Key messages
 AKI is common in patients admitted after CA.
 Major risk-factors for AKI are older age, chronic
renal disease, higher dose of epinephrine, in-hospital
CA, presence of shock during the ICU stay, low
creatinine clearance (CrCl) on admission and a
high cumulative fluid balance at 48 h.
 AKI was not an independent predictor of poor
3-month neurological outcome.
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